是否SGLT2is改善了晚期心力衰竭的成年人的终身护理?
Media Mokhtarnia1,2, Kieran L Quinn1
1Temmy Latner Centre for Palliative Care and Division of Internal Medicine and Geriatrics, Department of Medicine, Sinai Health System, University of Toronto, Toronto, ON.
NEJM evidence
|October 28, 2025
概括
-葡萄糖携带载体-2 抑制剂 (SGLT2 抑制剂) 可能改善晚期心力衰竭患者的治疗结果. 需要进一步的试验来确认复杂病例和生命末期护理的益处.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 老年病的医生 老年病的医生
背景情况:
- -葡萄糖携带载体-2 抑制剂 (SGLT2 抑制剂) 在心力衰竭 (HF) 患者中显示有好处.
- 现有的试验往往排除了高级HF和多种并发症的个体.
- SGLT2 抑制剂对晚期高血压中以患者为中心的结局的影响仍在调查中.
研究的目的:
- 审查目前关于SGLT2抑制剂在心力衰竭中的证据.
- 建议开展一项临床试验,研究SGLT2抑制剂在晚期高血压炎患者中的作用.
- 为了确定SGLT2抑制剂是否可以改善晚期HF患者的终身护理.
主要方法:
- 对SGLT2抑制剂和心力衰竭的现有文献的综述.
- 关于新的临床试验设计的建议.
- 专注于以患者为中心的结果和终身护理.
主要成果:
- 现有证据主要支持SGLT2抑制剂在不那么复杂的HF群体.
- 关于高级HF与多种慢性疾病的安全性和有效性的数据是有限的.
- 拟议的试验旨在填补这一知识缺口.
结论:
- 进一步的研究至关重要,以确定SGLT2抑制剂在高级HF中的作用.
- 调查以患者为中心的结果,包括终身护理,至关重要.
- SGLT2 抑制剂可能有好处,但需要在复杂人群中进行具体研究.
相关概念视频
Heart Failure V: Medical Management
209
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
209
Heart Failure VI: Adjunct Therapies
246
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
246
Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
232
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
232
Heart Failure VII: Nursing Interventions
410
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
410
